CA
CGEM icon

Cliff Asness’s Cullinan Oncology CGEM Stock Holding History

Cliff Asness’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
581,338
+220,464
+61% +$3.27M ﹤0.01% 1540
2026
Q1 		$5.13M Buy
360,874
+79,391
+28% +$1.02M ﹤0.01% 1729
2025
Q4 		$2.91M Buy
281,483
+83,563
+42% +$754K ﹤0.01% 1895
2025
Q3 		$1.17M Buy
197,920
+177,000
+846% +$1.3M ﹤0.01% 2329
2025
Q2 		$158K Buy
+20,920
New +$168K ﹤0.01% 3103
2023
Q4 		– Sell
-21,774
Closed -$197K – 2344
2023
Q3 		$197K Sell
21,774
-50,048
-70% -$521K ﹤0.01% 2146
2023
Q2 		$773K Sell
71,822
-16,470
-19% -$175K ﹤0.01% 1657
2023
Q1 		$903K Sell
88,292
-23,068
-21% -$254K ﹤0.01% 1585
2022
Q4 		$1.17M Buy
111,360
+2,958
+3% +$35.9K ﹤0.01% 1500
2022
Q3 		$1.39M Buy
108,402
+87,493
+418% +$1.18M ﹤0.01% 1366
2022
Q2 		$268K Buy
+20,909
New +$237K ﹤0.01% 1900

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Cliff Asness's CGEM Position: Q2 2026 in Review

Cliff Asness increased its Cullinan Oncology (CGEM) stake by 61% in Q2 2026, buying an estimated $3.27M and bringing the position to 581,338 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

Cliff Asness first reported a position in CGEM in Q2 2022 and has held it in 11 quarters since. 182 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Cliff Asness held 581,338 shares of Cullinan Oncology worth $10.6M as of Q2 2026.
  • Cliff Asness bought 220,464 Cullinan Oncology shares in Q2 2026, an estimated $3.27M.
  • Cullinan Oncology made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1540 holding.
  • Cliff Asness first reported a position in Cullinan Oncology in Q2 2022 and has held it in 11 quarters since.
  • 182 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.